Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer

Abstract In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel ex...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alessandro De Vita, Chiara Liverani, Roberto Molinaro, Jonathan O. Martinez, Kelly A. Hartman, Chiara Spadazzi, Giacomo Miserocchi, Francesca Taraballi, Michael Evangelopoulos, Federica Pieri, Alberto Bongiovanni, Laura Mercatali, Ennio Tasciotti, Toni Ibrahim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f3592b74807643ad8fc46e879476242d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3592b74807643ad8fc46e879476242d
record_format	dspace
spelling	oai:doaj.org-article:f3592b74807643ad8fc46e879476242d2021-12-02T13:30:51ZLysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer10.1038/s41598-021-84492-32045-2322https://doaj.org/article/f3592b74807643ad8fc46e879476242d2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84492-3https://doaj.org/toc/2045-2322Abstract In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel extracellular matrix (ECM)-targeting nanotherapeutic was engineered using a lipid-based nanoparticle chemically linked to an inhibitor of the ECM-related enzyme, lysyl oxidase 1 (LOX), that inhibits the crosslinking of elastin and collagen fibers. We demonstrated that, when the conjugated vesicles were loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breast cancer (TNBC) cell growth was observed both in vitro and in vivo. Moreover, in vivo results displayed prolonged survival, minimal cytotoxicity, and enhanced biocompatibility compared to free epirubicin and epirubicin-loaded nanoparticles. This all-in-one nano-based ECM-targeting chemotherapeutic may provide a key-enabling technology for the treatment of TNBC.Alessandro De VitaChiara LiveraniRoberto MolinaroJonathan O. MartinezKelly A. HartmanChiara SpadazziGiacomo MiserocchiFrancesca TaraballiMichael EvangelopoulosFederica PieriAlberto BongiovanniLaura MercataliEnnio TasciottiToni IbrahimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alessandro De Vita Chiara Liverani Roberto Molinaro Jonathan O. Martinez Kelly A. Hartman Chiara Spadazzi Giacomo Miserocchi Francesca Taraballi Michael Evangelopoulos Federica Pieri Alberto Bongiovanni Laura Mercatali Ennio Tasciotti Toni Ibrahim Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
description	Abstract In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel extracellular matrix (ECM)-targeting nanotherapeutic was engineered using a lipid-based nanoparticle chemically linked to an inhibitor of the ECM-related enzyme, lysyl oxidase 1 (LOX), that inhibits the crosslinking of elastin and collagen fibers. We demonstrated that, when the conjugated vesicles were loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breast cancer (TNBC) cell growth was observed both in vitro and in vivo. Moreover, in vivo results displayed prolonged survival, minimal cytotoxicity, and enhanced biocompatibility compared to free epirubicin and epirubicin-loaded nanoparticles. This all-in-one nano-based ECM-targeting chemotherapeutic may provide a key-enabling technology for the treatment of TNBC.
format	article
author	Alessandro De Vita Chiara Liverani Roberto Molinaro Jonathan O. Martinez Kelly A. Hartman Chiara Spadazzi Giacomo Miserocchi Francesca Taraballi Michael Evangelopoulos Federica Pieri Alberto Bongiovanni Laura Mercatali Ennio Tasciotti Toni Ibrahim
author_facet	Alessandro De Vita Chiara Liverani Roberto Molinaro Jonathan O. Martinez Kelly A. Hartman Chiara Spadazzi Giacomo Miserocchi Francesca Taraballi Michael Evangelopoulos Federica Pieri Alberto Bongiovanni Laura Mercatali Ennio Tasciotti Toni Ibrahim
author_sort	Alessandro De Vita
title	Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
title_short	Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
title_full	Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
title_fullStr	Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
title_full_unstemmed	Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
title_sort	lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f3592b74807643ad8fc46e879476242d
work_keys_str_mv	AT alessandrodevita lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT chiaraliverani lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT robertomolinaro lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT jonathanomartinez lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT kellyahartman lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT chiaraspadazzi lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT giacomomiserocchi lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT francescataraballi lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT michaelevangelopoulos lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT federicapieri lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT albertobongiovanni lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT lauramercatali lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT enniotasciotti lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer AT toniibrahim lysyloxidaseengineeredlipidnanovesiclesforthetreatmentoftriplenegativebreastcancer
_version_	1718392950094823424

Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer

Ejemplares similares